Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Therapeutic targets in radiotherapy
Autore:
Brown, JM;
Indirizzi:
Stanford Univ, Sch Med, Div Radiat Biol, Dept Radiat Oncol, Stanford, CA 94305 USA Stanford Univ Stanford CA USA 94305 Radiat Oncol, Stanford, CA 94305 USA
Titolo Testata:
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
fascicolo: 2, volume: 49, anno: 2001,
pagine: 319 - 326
SICI:
0360-3016(20010201)49:2<319:TTIR>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
GROWTH-FACTOR RECEPTOR; SQUAMOUS-CELL CARCINOMA; PREDICTS RADIATION RESPONSE; OXYGENATION PREDICTS; TUMOR HYPOXIA; FARNESYLTRANSFERASE INHIBITOR; MONOCLONAL-ANTIBODIES; UTERINE CERVIX; RAS ONCOGENES; IN-VITRO;
Keywords:
ras; farnesyltransferase inhibitors; epidermal growth factor receptors; C-225; tumor hypoxia; tirapazamine; cisplatin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
50
Recensione:
Indirizzi per estratti:
Indirizzo: Brown, JM Stanford Univ, Sch Med, Div Radiat Biol, Dept Radiat Oncol, CCSRS,Room 1255, Stanford, CA 94305 USA Stanford Univ CCSR S,Room 1255 Stanford CA USA 94305 A 94305 USA
Citazione:
J.M. Brown, "Therapeutic targets in radiotherapy", INT J RAD O, 49(2), 2001, pp. 319-326

Abstract

Background: Enormous progress has been made in the past 5 years in our understanding of the gene products governing the response of mammalian cells to ionizing radiation, Many of these are potential targets for enhancing theeffectiveness of radiotherapy. However, a major barrier to such efforts isthe requirement for a preferential effect on tumor vs. normal cells. Such a requirement can only come about by exploiting a known difference between tumor and normal cells,Methods: This review highlights three differences between tumor and normalcells that are being exploited with fractionated radiotherapy. Results: The three strategies to enhance preferentially tumor response to radiotherapy are inhibition of ras activity using farnesyltransferase inhibitors (FTIs), inhibition of epidermal growth factor receptors (EGFRs), and the use of drugs that preferentially kill hypoxic cells, Each of these strategies exploits a known difference between at least some tumors and their surrounding normal tissues, and each has shown encouraging results when combined with fractionated radiation in preclinical studies. Conclusions: For each of the three strategies to enhance preferentially the sensitivity of cancers, the preclinical and early clinical data are promising for their successful application in radiotherapy, (C) 2001 Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/09/20 alle ore 00:56:46